$10.59▴ 3.32%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$-1.06BTTM operating cash
Pre-profit
It is still burning cash while pre-profit.
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
Not enough data yet
Not enough revenue history to measure growth.
Leverage
Not enough data yet
Term-debt data is not available for this company.
More coming: dilution / share-count creep.
✦ The read
Revolution Medicines, Inc. is pre-profit. It is still burning cash while pre-profit.
Key numbers
Valuation
EPS (TTM)$-7.10
TTM (trailing 12 months, through fiscal Q1 FY2026)
Size
Revenue (TTM)$0.00
TTM (trailing 12 months, through fiscal Q1 FY2026)
Recent news
Sentiment · last 30 days11 articles
2 bullish9 neutral0 bearish
Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP Before Application Deadline
MONDAY DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - ERAS
ERASCA LEAD PLAINTIFF DEADLINE AUGUST 10th: Bragar Eagel & Squire, P.C. Reminds Erasca, Inc. (ERAS) Investors with Large Losses to Contact the Firm Regarding their Rights
Robbins LLP Reminds Erasca, Inc. Investors of the Pending Lead Plaintiff Deadline in the Securities Fraud Class Action; Contact the Firm to Learn About Your Rights
Signals and key numbers are from the fiscal Q1 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.